New oral pill H021 aims to tame Crohn's Flare-Ups
NCT ID NCT07677514
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether an experimental oral tablet called H021 can help people with moderate to severe Crohn's disease. Participants receive either a low or high dose of H021 or a placebo for 12 weeks, with an option to continue treatment. The study measures symptom improvement and healing of the gut lining using endoscopy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
H021
What this could lead to
If successful, H021 could offer a new oral treatment option for people with moderate to severe Crohn's disease, potentially reducing symptoms and intestinal inflammation.
What could go wrong
This is an early phase 2 trial with a small number of participants. The drug may not prove more effective than placebo, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AdventHealth Medical Group Inflammatory Bowel Disease Clinic at Orlando
Orlando, Florida, 32804, United States
Contact
-
Alliance Medical Research - Lighthouse Point
Lighthouse PT, Florida, 33064, United States
Contact
-
Anhui Provincial Hospital
Hefei, China
-
Chongqing General Hospital
Chongqing, China
-
Huizhou Central People's Hospital
Huizhou, China
-
Huizhou First People's Hospital
Huizhou, China
-
Jiujiang First People's Hospital
Jiujiang, China
-
Medical Research Center of Connecticut
Hamden, Connecticut, 06514, United States
Contact
-
Peking University First Hospital
Beijing, China
Contact
-
Shengjing Hospital of China Medical University
Shenyang, China
Contact
-
Shenzhen Longhua District People's Hospital
Shenzhen, China
-
Taihe Hospital
Shiyan, China
-
The Central Hospital of Wuhan
Wuhan, China
-
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China
-
The First Affiliated Hospital of Fujian Medical University
Fujian, China
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
Contact
-
The First Hospital of Quanzhou, Fujian Medical University
Fujian, China
-
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, China
-
The Second Xiangya Hospital of Central South University
Changsha, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
-
Xiangya Hospital of Central South University
Changsha, China
-
Yuebei People's Hospital
Shaoguan, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, China
-
Zhuzhou Central Hospital
Zhuzhou, China